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Abstract
Background: Intermittent preventive treatment (IPTp) is efficacious in reducing the adverse outcomes
associated with pregnancy-associated malaria, however uptake of the recommended two doses is low in
Tanzania, and little is known of the timepoint during pregnancy at which it is delivered. This study
investigated the timing of delivery of IPTp to pregnant women attending antenatal clinics (ANC), and the
potential determinants of timely uptake.
Methods: Structured interviews were conducted with staff and pregnant women at antenatal clinics in
northeast Tanzania, and antenatal consultations were observed. Facility-based and individual factors were
analysed for any correlation with timing of IPTp uptake.
Results: Almost half the women interviewed first attended ANC during or before the fourth month of
gestation, however 86% of these early attendees did not receive IPTp on their first visit. The timing of IPTp
delivery complied closely with the national guidelines which stipulate giving the first dose at 20–24 weeks
gestation. Uptake of at least one dose of IPTp among women who had reached this gestation age was 67%,
although this varied considerably between clinics. At one facility, IPTp was not delivered because SP was
out of stock.
Conclusion: Early uptake of IPTp was found to be hampered by factors external to health worker
performance or women's individual preferences. These include insufficient drug stocks and an apparent
lack of information to health workers on the reasoning for continued use of SP for IPTp when it has been
replaced as a first-line treatment. In addition, an unexpectedly high proportion of women attend antenatal
clinics before 20 weeks of pregnancy. While current policy denies the use of IPTp at this time, there is
emerging, but incomplete, evidence that malaria in early pregnancy may contribute considerably to the
burden of pregnancy-related malaria. Current policy may thus result in a missed opportunity for
maximising the benefit of this intervention, and efforts to encourage earlier attendance at ANC alone are
unlikely to improve uptake of IPTp. More evidence is needed to weigh the benefits of early IPTp use against
theoretical risks of antifolate drugs in early pregnancy.
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Background
Malaria infection during pregnancy has adverse conse-
quences for both the woman and foetus, accounting for
an estimated 26% of severe maternal anaemia in sub-
Saharan Africa [1] and causing an estimated 100,000 –
200,000 infant deaths each year through low birth weight
[2,3]. To address this burden, the World Health Organiza-
tion recommends a package of interventions including
intermittent preventive treatment (IPTp) with the anti-
malarial drug sulphadoxine-pyrimethamine (SP) at least
twice during the second and third trimesters of pregnancy,
use of insecticide-treated bednets (ITNs) and effective case
management [4]. The efficacy of IPTp in reducing mater-
nal parasitaemia and anaemia has been demonstrated in
several studies[5-7], and the WHO strategy has now been
adopted by almost all malaria-endemic countries in Africa
[8].
In Tanzania, it is national policy to offer SP to all pregnant
women attending antenatal clinics [9] at between 20 and
24 weeks gestation for the first dose and between 28 and
32 weeks for the second dose [10]. It is estimated that
uptake of IPTp amongst Tanzanian women who delivered
in 2005/06 was 70% for one dose but only 35% for two
doses [11]. Previous studies have reported a range of fac-
tors associated with incomplete coverage of IPTp, includ-
ing late first attendance at the antenatal clinic [12,13],
shortages of staff or drug supply, poor health worker
skills, informal charges for IPTp, and inequitable access to
ANC services [12]. Individual characteristics that have
been found to correlate with no or incomplete IPTp
uptake are multigravidity [14] and lack of knowledge of
the consequences of malaria in pregnancy [15].
Relatively little is known about the timing of delivery of
the first dose of IPTp to pregnant women, however this
may influence whether subsequent doses are given and
may also be important in terms of time spent at risk of
malaria, given the growing evidence that malaria in early
pregnancy may be the cause of a significant proportion of
the burden of pregnancy-related malaria. There is evi-
dence that parasitaemia is highest in the second trimester
of pregnancy [16] and that malaria infection during the
first trimester may lead to low birthweight [17], and thus
the efficacy of IPTp may depend not only on overall
uptake, but also the time point during pregnancy at which
it is received. This study examined the timing of delivery
of IPTp to pregnant women attending antenatal clinics in
northeast Tanzania, in the context of national, individual
and facility-related determinants of timely uptake of IPTp.
Methods
Study design and population
Data were collected on the delivery of intermittent preven-
tive treatment during pregnancy from three sources: exit
interviews with pregnant women attending antenatal clin-
ics, interviews with antenatal clinic staff and observations
of consultations at antenatal clinics. The study was con-
ducted over a three-week period during July 2006, at six
antenatal facilities in three districts within the Tanga
region of northeast Tanzania: Korogwe, Pangani and
Tanga. The choice of region was based on its high malaria
transmission characteristics [18] and the districts were
purposively selected to represent urban, peri-urban and
rural settings respectively, which may be associated with
different malaria transmission patterns and/or access to
health care facilities and preventive interventions. Malaria
transmission in this region, measured by the mean
number of infected bites per person per year (entomolog-
ical inoculation rate) has been estimated at 100 to 500,
although this may be reduced by up to 75% where insec-
ticide-treated bednets are widely used [19]. Prevalence of
parasitaemia in the adult population in the study area has
been estimated at greater than 20% [20]. Coverage of
insecticide-treated nets has been measured at 16% across
the >12 year-old population in one district of Tanga
region during the period 2001–2005 [21] and at 18%
among pregnant women in Tanzania as a whole at the
time of the current study [11].
Within each district, two health facilities providing ante-
natal services were selected following consultation with
the respective District Medical Officer – in each case the
district hospital plus one smaller facility. This was
intended to be a small descriptive study that would high-
light potential areas for subsequent larger surveys. Within
the time and resources available it was not possible to
obtain a large and random sample of facilities, which
would have permitted better generalizability of the results
to the broader population. However, the facilities chosen
represent the range of levels and settings of health care at
which antenatal services are provided, which permits at
least an evaluation of the variability in practices between
health facilities.
All women attending a study site antenatal clinic on the
two scheduled days were approached for recruitment into
the study, and written informed consent was obtained
from all participants. A sample of consultations at each
antenatal clinic were observed, and two health staff were
interviewed at each facility. Written informed consent was
obtained from all participants.
Survey procedures
Interviews were conducted in Kiswahili. Study partici-
pants were asked a series of closed questions about their
socio-economic background, pregnancy history, attend-
ance at antenatal clinic and their use of malaria preventive
interventions throughout pregnancy, as well as several
open questions exploring reasons for not having used cer-
Malaria Journal 2008, 7:79 http://www.malariajournal.com/content/7/1/79
Page 3 of 7
(page number not for citation purposes)
tain interventions. Interviews with health workers con-
sisted of a mixture of closed and open questions,
addressing the attitudes and practices of staff in discussing
malaria with pregnant women, and administering IPTp.
Notes on observed consultations were taken according to
pre-determined categories of interest to the study, which
were discussions on malaria in pregnancy and the use of
intermittent preventive treatment to protect against
malaria.
Data analysis
Data were double entered and validated using EpiData
version 3.1 (the EpiData Association, Denmark) and ana-
lysed in Stata 9.0 (StataCorp LP, USA). Qualitative data
from interviews was re-coded numerically to permit quan-
titative analysis of the key themes, using a consistent and
exhaustive coding frame developed retrospectively to
reflect the full range of responses. The majority of analyses
were descriptive; Chi-squared tests were used to compare
frequencies of outcomes of interest between facilities and
to seek evidence for an association between key potential
explanatory variables and the study outcomes.
Results
Study population
A total of 133 pregnant women were recruited to the study
across the six sites, of whom 119 were interviewed (Table
1). Approximately half of the total respondents came
from the two busy urban antenatal clinics (ANC) in Tanga
district, as the sample size at each facility was determined
by the number of women attending on the study days.
Loss of some study participants between recruitment and
interview occurred in all but one of the sites, and was due
largely to the participant leaving the clinic directly after
her consultation instead of being directed to the interview
room.
The median age of respondents was 24 years (range 16 –
44 years). The educational level of the study population
varied between sites, with the proportion having com-
pleted primary education ranging from 46% to 92%
(average of 76%). Approximately 30% of all respondents
were in their first pregnancy, with the median month of
gestation 6 months (range 2 – 10 months). Thirty-nine
percent of respondents were attending the antenatal clinic
for the first time on the day of interview, with a median of
two ANC visits made by respondents (range 1–6). A total
of 50 consultations were observed across the study sites,
which represented 38% of the total participants (range 0
– 100%), and between one and three staff were inter-
viewed at each clinic.
Attendance at antenatal clinics
On interview 75% of respondents reported having first
attended an antenatal clinic during the second trimester of
pregnancy, and 93% had attended at least once before the
third trimester. Among the eight respondents (7%) whose
first ANC visit was later than the second trimester, the rea-
sons given for late attendance were: having had no prob-
lems during pregnancy and therefore no need to visit the
clinic; a long distance to travel from home to the clinic;
inability to leave farm work to travel into town; and think-
ing she was earlier on in gestation than she actually was.
To further investigate the timeliness of ANC attendance, a
categorization of 'early first attendance' was defined as a
first visit to ANC at or before 4 months gestation, com-
pared to the national average of 19.6 weeks [11] and prior
to the scheduled delivery of the first IPTp dose of 20–24
weeks [10]. Across all six facilities, almost half (48%) of
all respondents had attended ANC at or before four
months of gestation, within a range of 40% to 70% at
individual facilities. Primigravid respondents were more
likely than multigravid women to have attended ANC
early (63.9% vs 41.5%; chi-squared test P = 0.025), but no
other determinants of early first attendance were identi-
fied.
Table 1: Characteristics of study population by facility
District (setting) Pangani (rural) Tanga (urban) Korogwe (peri-urban) TOTAL
Facility level District 
Hospital
Dispensary District 
Hospital
Health 
Centre
District 
Hospital
Dispensary
Women interviewed 17 13 32 28 19 10 119†
Primigravid 35.3% 30.8% 34.4% 28.6% 31.6% 10.0% 30.3%
Attended health education 
class so far this pregnancy
52.9% 75.0% 65.6% 100% 57.9% 60.0% 71.2%
Median years of age (range) 22 (17–38) 20 (17–35) 26 (18–40) 23.5 (18–36) 25 (16–36) 27.5 (19–44) 24 (16–44)
Median month of gestation 
(range)
5 (3–9) 7 (3–10) 6 (3–9) 6 (3–9) 7 (2–10) 6 (4–9) 6 (2–10)
†An additional 14 women across 5 of the 6 study sites were recruited to the study but did not return for interview following their consultation
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Use of anti-malarials during pregnancy
Eighty percent of women had heard of intermittent pre-
ventive treatment (IPTp) with sulphadoxine-pyrimeth-
amine (SP) to prevent malaria in pregnant women and
55% of respondents reported receiving at least one dose of
IPTp. Table 2 presents the data on use of IPTp by facility,
and also categorizes the respondents by gestation age, to
account for their different exposure times. The outcome of
having received one dose of IPTp (among those ≥5
months gestation) or two doses of IPTp (among those ≥7
months gestation) was associated in bivariate analysis
only with the antenatal facility attended (chi-squared test
for association; P = 0.001), and not with any other indi-
vidual characteristics, including age, marital status, socio-
economic status, education level, attendance at health
education or timing of first ANC visit.
Timing of IPTp delivery
The timing of first IPTp dose within the study population
is illustrated in Figure 1 and demonstrates that when IPTp
was given, it was generally first given during the fifth or
sixth month of gestation. This is consistent with the
national guidelines for delivery of IPTp, which recom-
mends giving the first dose between 20 and 24 weeks ges-
tation and the second dose between 28 and 32 weeks
gestation [10]. According to the respondents' reports, 13%
(8/63) of first IPTp doses were given earlier than the
scheduled timing of five months gestation, however Fig-
ure 1 also shows that almost half of the total respondents
attended ANC prior to five months gestation, and thus the
large majority of those early attendees (49/57; 86%) were
not given IPTp on that first visit.
Barriers to the delivery of IPTp
For those who did not receive IPTp as scheduled, the key
reason reported was that it was not offered by ANC staff.
Only one woman said she had refused SP when given, due
to perceived negative physical effects.
Of the 12 ANC staff interviewed, all said they knew the
schedule for delivery of IPTp and 8/12 (67%) could
describe it correctly (3/12, 25% partly correctly; 1/12, 8%
incorrectly). The only two reports of deviation from the
IPTp schedule were in giving an additional SP dose out-
side the recommended time windows, however two staff
at one clinic also reported that SP was not currently
stocked in their clinic for use in IPTp.
The observations of consultations were limited by the fact
that women of different gestation ages and number of
Table 2: Use of anti-malarial drugs during pregnancy
District Pangani Tanga Korogwe TOTAL
Facility level District Hospital Dispensary District Hospital Health Centre District Hospital Dispensary
Respondents per 
facility
17 13 32 28 19 10 119
Any anti-malarials 
taken during this 
pregnancy
As treatment, n 
(%)
3 (17.7) 2 (15.4) 8 (25.0) 5 (17.9) 4 (21.1) 1 (10.0) 23 (19.3)
As prevention, 
n (%)
12 (70.6) 9 (69.2) 12 (37.5) 14 (50.0) 11 (57.9) 9 (90.0) 67 (56.3)
Heard of IPTp, n 
(%)
14 (82.4) 11 (84.6) 19 (59.4) 24 (85.7) 18 (94.7) 10 (100) 96 (80.7)
Received any 
doses IPTp†
Overall, n (%) 9 (52.9) 7 (53.9) 11 (34.4) 15 (53.6) 14 (73.7) 9 (90.0%) 65 (54.6)
Uptake among 
those ≥ 5 
months 
gestation*
64.3% 77.8% 40.0% 62.5% 100% 100% 67.0%
Received ≥ 2 
doses IPTp†
Overall, n (%) 7 (41.2) 5 (38.5) 4 (12.5) 5 (17.9) 6 (31.6) 4 (40.0) 31 (26.1)
Uptake among 
those ≥ 7 
months 
gestation**
87.5% 75.0% 16.7% 30.8% 85.7% 66.7% 48.2%
†Respondents who had not heard of IPTp were not asked about doses received
*Denominator is number of respondents who were 5 months gestation or later
**Denominator is number of respondents who were 7 months gestation or later
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prior visits received different information and interven-
tions, however they did highlight the variability between
facilities in the degree to which IPTp was discussed and
delivered, and specifically that women at four months or
less gestation were commonly told that they should come
back at five months to receive the first dose of IPTp, as was
reported also by the women themselves in interview. Data
from observations of consultations also confirmed that at
the facility in which IPTp coverage was lowest, staff were
currently not dispensing SP at all. At this clinic, patients
were told that SP was out of stock and that they would
need to purchase it elsewhere, however the cross-sectional
nature of this study meant that it was not possible to
determine whether these women did obtain SP from
another source, nor how long SP remained out of stock at
this clinic.
Discussion
The results of this study suggest that the timely uptake of
malaria preventive interventions by pregnant women in
this region of north-east Tanzania depends more on the
practices of health workers at the antenatal clinic (ANC)
attended, rather than the individual characteristics of the
pregnant woman or the timing of her first attendance at
ANC.
Early ANC attendance – a missed opportunity for timely 
delivery of IPTp
The vast majority of respondents attended ANC at least
once before the third trimester of pregnancy, and approx-
imately half made their first visit early, ie. during or before
the fourth month of gestation, which is consistent with
other reports of ANC attendance in Tanzania [11]. How-
ever, no evidence was found of an association between
early ANC attendance and uptake of intermittent preven-
tive treatment (IPTp), a key malaria preventive strategy.
This suggests that efforts to encourage timely ANC attend-
ance alone are unlikely to improve the uptake of this
intervention, at least where other barriers to delivery exist.
Although the coverage of IPTp was variable among the
study sites, where it was given by antenatal clinics the tim-
ing of delivery was generally in accordance with the
national guidelines [10]. Knowledge of the recommended
schedule for delivery of IPTp was high among clinic staff,
and the guidelines were well-publicized with several clin-
ics displaying posters and most providing pamphlets
describing the appropriate gestation ages for first and sec-
ond doses. Although this demonstrates the effectiveness
of clear and simple guidelines in achieving high compli-
ance, the narrow gestational range specified by the sched-
ule limits the potential benefit of IPTp early in pregnancy.
A large proportion of women in this study who attended
ANC at four months gestation or earlier were required to
wait until a later visit in order to receive IPTp, delaying the
benefits of treatment and risking the possibility that they
do not return for a second antenatal visit. This represents
a missed opportunity for early delivery of this important
intervention, and suggests that encouragement of earlier
ANC attendance could have only a limited effect on the
uptake of IPTp. Recent evidence in HIV-positive women
in Zambia suggests that two or more doses of IPTp deliv-
ered between 16 and 36 weeks gestation is associated with
improved maternal and foetal outcomes compared with a
single dose, but with a threshold effect of little marginal
benefit above two doses [22]. Whether this principle
extends to non-HIV infected women and to delivery of
IPTp in the early weeks of the second trimester is not
known but seems highly plausible, and these results high-
light the importance of maximising the proportion of
women accessing the recommended two doses of IPTp.
The national policy in Tanzania for first-line treatment of
malaria has changed to the artemisinin-based combina-
tion drug artemether-lumefantrine, in the face of growing
resistance to the conventional anti-malarials chloroquine
and SP [10]. The guidelines for use of SP for IPTp remain
unchanged however, as the efficacy requirement for pre-
sumptive treatment is not as high as for treatment of clin-
ical malaria [10] and the safety of artemether-
lumefantrine in pregnancy is not yet established [23]. The
present study identified potential confusion at the clinic
level around this policy change. In one facility SP was not
stocked and of the women interviewed in this clinic, one
reported that she had been told that the hospital had
stopped its distribution of SP for the moment, and
another that SP had 'expired' and was no longer function-
ing. Although the staff interviewed at this clinic confirmed
that SP was out of stock, the interview questionnaire did
Comparison of timing of first attendance at antenatal clinic with tim ng of irst dose of IPTpFigure 1
Comparison of timing of first attendance at antenatal 
clinic with timing of first dose of IPTp. *Information 
missing for one respondent. **Information missing for two 
respondents.
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not permit further investigation of the reasons for this or
the perceived implications of the policy change on the use
of SP for IPTp. The lack of SP at this clinic presented a bar-
rier to the timely delivery of IPTp, and the indication that
this may be due to confusion over the change in malaria
treatment policy highlights the need for training and dis-
semination of information to the periphery as part of the
implementation of the new policy.
The data on the uptake of IPTp reported here is limited in
its generalizability beyond the study population, due to
the small sample size of both facilities and individual
respondents. Although clinics were selected to represent a
range of settings and levels of health facility, sampling was
not done randomly and therefore may be a source of bias.
However, the national guidelines determining the timing
of delivery of IPTp apply throughout Tanzania, and
although the timing of first attendance at antenatal care
may vary within other populations, the pattern observed
in this study was consistent with other reports of ANC
attendance in Tanzania [11]. This suggests that the results
presented here may apply elsewhere in Tanzania, at least
where there is early ANC attendance, and justify a larger
survey to further investigate the issues of timing and exter-
nal constraints to delivery of IPTp.
Potential benefits and risks of earlier delivery of IPTp
There is currently little known about the effect of malaria
in early pregnancy on pregnancy outcomes [24]. How-
ever, the prevalence and severity of malaria infection is
known to be highest during early pregnancy [16] and a
recent review of the pathogenesis of malaria-associated
foetal growth restriction hypothesized a mechanism by
which malaria infection early in pregnancy may impair
placental blood flow, leading to poor pregnancy out-
comes [25]. Some evidence of an effect of malaria infec-
tion during the first trimester on low birthweight has also
been reported by others [17], and together this evidence
suggests that the maximum benefit of IPTp may be gained
by delivery of the first dose early in pregnancy. This poten-
tial benefit needs to be weighed against any potential risks
associated with delivery of SP early in pregnancy, given
theoretical concerns over the association of folate antago-
nists with neural tube defects and other congenital abnor-
malities [26,27]. However, SP has a very good safety
profile in pregnancy with extensive clinical trial data sup-
porting its safety when delivered in the second and third
trimesters [28], and is considered by the WHO to be one
of the anti-malarial drugs that is safe to use for treatment
during the first trimester of pregnancy [23]. The consider-
able evidence for the safety of SP during the second tri-
mester of pregnancy, and the observation in this study
that up to 75% of women may first attend antenatal clinic
during the second trimester, support the conclusion that
it may be operationally possible, safe and of potential
benefit to maternal health to offer the first dose of IPTp
earlier in the second trimester than is currently prescribed
by Tanzanian national guidelines.
While SP continues currently to be recommended for use
in IPTp, growing drug resistance especially in East Africa
means that an alternative is likely to be required in the
near future. The efficacy and safety of many candidate
anti-malarials has not yet been demonstrated in pregnant
women [29], and there is some indication from animal
models that artemisinin compounds may be associated
with early pregnancy loss, although this has not been
observed in the limited human data [29]. Further research
is needed both to establish the effect of malaria infection
at different gestational stages on pregnancy outcomes,
and to examine the safety profile of intermittent delivery
of SP and other candidate anti-malarials during the first
half of pregnancy, thus providing evidence to inform the
timing of delivery of preventive interventions.
Conclusion
Where IPTp has been adopted as part of a national policy
for malaria control, ongoing research is needed into oper-
ational barriers to its delivery. These barriers may be com-
mon to many implementation settings within and
between countries. Given the observation in this study of
generally good adherence by clinic staff to the national
IPTp dosing schedule, a change in policy in Tanzania to
recommend earlier delivery of the first dose of SP (for
example at 4 months gestation) may improve IPTp cover-
age in areas where a large proportion of women attend
ANC early in pregnancy. At the same time, local variations
in availability of SP at antenatal clinics need to be recog-
nized and addressed, in particular to provide accurate
information about current guidelines for SP use as IPTp,
in the context of increasing SP resistance and the change
in policy for first-line malaria treatment.
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